Dr. Mitchell Brin MD

• 
  videoshelf.com/blog/?paged=3 - [Cached Version]
  Published on: 5/4/2009    Last Visited: 5/22/2009  

  "One of the advantages of BOTOX(R) therapy is its highly selective mechanism of action and targeted mode of administration, via injection directly into the affected muscle or gland, which in large part explains the product's clinical performance and predictable patient outcomes," explained Mitchell F. Brin, M.D., Allergan's Senior Vice President of Global Development and Chief Scientific Officer for BOTOX(R). No Two Botulinum Toxins Are Alike With additional botulinum toxin products awaiting FDA approval, Dr. Brin reviewed the scientific differences among botulinum toxin therapies and the factors that physicians and patients should weigh when considering treatment options. "The well-established risk/benefit profile of BOTOX(R) is unique to the product, because no two botulinum toxins are alike," said Dr. Brin. He pointed out that botulinum toxin products are biologics - i.e., derived from living substances, in this case, from the Clostridium botulinum bacteria. This bacteria produces seven different subtypes of botulinum toxin, with type A being the most potent. Differences among subtypes may influence therapeutic effects and how long they last, or the occurrence of adverse events following treatment. Even among botulinum toxin products of the same subtype, variations in manufacturing processes can result in differences in the product's characteristics, including formulation (e.g., molecular uniformity and weights of toxin complexes), pharmacokinetics, and clinical parameters such as efficacy, duration of effect, risk/benefit profile and immunogenicity. "Because of these differences, each botulinum toxin also has distinct dosing requirements," said Dr. Brin. "Importantly for physicians and patients, this means that BOTOX(R) is not interchangeable with other botulinum toxins and a physician cannot simply use a fixed-dose ratio and expect the same precise and predictable results." The Patient and Physician Experience While practicing in the 1980s at Columbia-Presbyterian Medical Center in New York City, Dr. Brin, a neurologist, co-led one of the first clinical trials of BOTOX(R) (Botulinum Toxin Type A) as a treatment for cervical dystonia supported by the Food and Drug Administration's Office of Orphan Product Development, when a young man named Tom Stampe was referred to him.
  ...
  After years of misdiagnosis and disability, I was finally referred to Dr. Brin who diagnosed my condition as cervical dystonia.

• 
  www.sabpa.org/web/news_details.php?ID=154 - [Cached Version]
  Published on: 1/1/2009    Last Visited: 10/17/2009  

  Mitchell Brin, MD, Senior Vice President, Global Drug Development & Chief Scientific Officer, Allergan, LLC. & Clinical Professor of Neurology, University of California, Irvine

• 
  www.evilhealth.com/tag/anti-aging - [Cached Version]
  Published on: 6/9/2009    Last Visited: 7/19/2009  

  As we understand it more, it gives us new ideas of how to use it," says Dr. Mitchell F. Brin, a neurologist who is the chief scientific officer for Botox at Allergan, the drug's maker.
  
  No other therapeutic agent "has so many demonstrated uses," he says.
  ...
  Dr. Brin of Allergan says Botox has a long safety track record - backed by 30 years of favorable research, studies on 11,000 people worldwide and 17 million treatments in the United States since 1994.
  
  "That safety profile has enabled us to continue to explore the product in deeper parts of the body and in more novel areas," Dr. Brin says. Allergan does not promote unapproved uses of the drug, he says.
  ...
  Botox doesn't work on stuttering, for example, because it involves too many parts of the anatomy - including the lips, the larynx and the tongue, says Dr. Brin of Allergan.
  
  "Stuttering is too complicated," Dr. Brin says a little wistfully.

• 
  www.sabpa.org/web/news_details.php?ID=167 - [Cached Version]
  Published on: 3/1/2009    Last Visited: 10/17/2009  

  Dr. Mitchell Brin, Senior Vice President at Allergan and Clinical Professor of Neurology at UC Irvine, presented the fascinating history and dramatic achievements of the Development of BOTOX.

• 
  www.sabpa.org/web/news_details.php?ID=161 - [Cached Version]
  Published on: 2/1/2009    Last Visited: 10/17/2009  

  Mitchell Brin, M.D., Senior Vice President, Global Drug Development & Chief Scientific Officer, Allergan, LLC. & Clinical Professor of Neurology, University of California, Irvine

• 
  care4dystonia.org/index.php/who-we-are/ - [Cached Version]
  Published on: 4/4/2007    Last Visited: 4/4/2007  

  Beka appeared on NBCs Dateline in 1998 with Dr. Mitchell Brin, MD in a story covering the use of Botox for dystonia.
  
  Since then she has appeared in multiple media venues, more often writing about her own experiences and battles with the disease in the 2 popular books I'm Moving Two and I'm Moving On…Are U??.

• 
  www.orthostatictremor.org/eleanor.html - [Cached Version]
  Published on: 2/8/2008    Last Visited: 2/8/2008  

  I then learned about Dr. Mitchell Brin, Associate Professor of Neurology and Director of the Movement Disorders Clinic at Mt. Sinai Hospital in New York City.He and his staff all but drooled when they saw a real, live OT case--we are so rare.He had me see a Dr. MacKinnon, a physiologist, who measured my tremors.All of these people were doing the same thing my home neurologist was doing: experimenting.

• 
  www.dystonia-foundation.org/health/default.asp?search=s - [Cached Version]
  Published on: 12/13/1999    Last Visited: 11/21/2006  

  Mitchell Brin, M.D.University of California, Irvine820 Gottschalk Medical PlazaIrvine, California 92697Tel: 714-456-7239

• 
  AAN Mentors - [Cached Version]
  Published on: 3/7/2001    Last Visited: 4/25/2002  

  Mitchell F. Brin, MDThe Mount Sinai Medical Center1 Gustave L Levy PlBox 1052New York NY 10029-6500(212) 241-5607; (212) 987-7363e-mail: mbrin@smtplink.mssm.edu

• 
  AAPP: American Academy of Pharmaceutical Physicians - [Cached Version]
  Published on: 12/25/2003    Last Visited: 9/4/2005  

  Speaker:Mitchell Brin, MD, Vice President, Development and Therapeutic Area Head, Allergan

Page:  1 2 3 4 5